Interested in a specialized area of hepatology? Join TLMdX's SIG sessions to exchange ideas with experts on trending topics. Sessions include:
Common Problems in Clinical Hepatology Practice | Clinical Practice SIG
What are the latest developments in managing patients with liver disease and cirrhosis? Join this engaging discussion by international experts, who will address management of portal vein thrombosis, interpretation of abnormal iron studies, managing acute kidney injury in hospitalized patients with liver disease, best practices for hepatocellular carcinoma and cholangiocarcinoma screening, and both pharmacologic and non-pharmacologic management of non-alcoholic steatohepatitis.
- Describe when to initiate anticoagulation for the treatment of portal vein thrombosis.
- To learn the differential diagnosis of abnormal iron studies and the proper evaluation of abnormal iron levels in the patient with liver disease.
- To learn the management of patients with acute kidney injury in the setting of cirrhosis, including data from recent studies regarding the treatment of hepato-renal syndrome.
- To understand proper screening for liver cancer and cholangiocarcinoma, in the setting of cirrhosis, non-alcoholic fatty liver disease without cirrhosis, and primary sclerosing cholangitis.
- To gain knowledge regarding recent advances in the management of non-alcoholic steatohepatitis, including strategies for weight loss and currently available pharmacologic therapy.
HBV: Current Management Controversies and the Road to Cure | Hepatitis B SIG
Currently, there is groundbreaking research on HBV cure efforts, therapeutic developments for HDV, virologic biomarkers to help individualize antiviral “stopping” strategies in selected populations, and our understanding of concurrent NAFLD and chronic HBV infection. This two-hour symposium reviews emerging data on a potential HBV cure and HDV treatments, novel virologic biomarkers, and the epidemiology and natural history of concurrent HBV/NALFD.
- Apply current knowledge in the epidemiology and natural history of concurrent HBV infection and NAFLD in the management of these patients.
- Interpret and use novel virologic biomarkers in the management of chronic HBV infection.
- Identify potential patients in whom safe stopping of antivirals can be considered and how to monitor these patients afterwards.
- Review updates in drug development for HBV cure – virologic, immunologic, and combination approach.
- Review updates in drug development for HDV.
Hot Topics in the Pathogenesis and Treatment of Liver Cancer (HCC and iCCA) | Hepatobiliary Neoplasia SIG & Liver Transplantation and Surgery SIG (Part 1)
This engaging session will explore hot topics in the management of liver cancer, including talks on hepatobiliary neoplasia and liver transplant. The program’s first segment will address advancements in research on the pathogenesis and surgical management of liver cancer, while the second half provides analysis of the newest advances in the systemic management of both iCCA and HCC.
- Review the advancements in the knowledge of the pathogenesis of the liver cancer.
- To update the information on management of ICCA and ICC, surgical, loco-regional and systemic treatment.
- To understand advancements in trial design for HCC.
- To understand the role of immunotherapy in the management of ICC and HCC.
The Basic Mechanisms of Hepatotoxicity and Their Clinical Implications | Hepatotoxicity SIG
Explore critical, clinically relevant topics related to basic mechanisms of hepatotoxicity at this SIG. Each talk begins with a patient case presented by a trainee. Discussion topics include how the hepatocyte responds to stress, including antibiotics and other medications; the genetic and epigenetic basis of drug-induced liver injury; and the interplay of adaptive immunity and liver injury.
- Discuss how the hepatocyte responds to stress; specifically, medications and other xenobiotics.
- Discuss the genetic and epigenetic basis of drug induced liver injury.
- Explain the interplay of adaptive immunity and liver injury.
- Discuss the environmental and occupational triggers for hepatotoxicity to better recognize potential causes of liver injury.
Clinical Management of NASH in 2020 | Nonalcoholic Fatty Liver Disease SIG
This symposium will focus on clinical management of NAFLD/NASH in 2020, at a time when the first NASH therapy is likely to be approved soon. Talks will explore whom to treat, how to identify these patients, current treatment options and the future of NASH diagnostics and therapy. The session includes a debate: Do we target NASH resolution or fibrosis improvement?
- Identify at-risk patients with NASH who would warrant potential therapy, different contexts of use for non-invasive tests and assessment of various therapies.
- Evaluate current treatment options for NASH to include non-pharmacologic treatment options.
- Assess the potential future therapeutic landscape for NAFLD/NASH.